A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS

NCT05788679 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Myelodysplastic Syndromes
Acute Myeloid Leukemia With Myelodysplasia Related Disease and < 30% Blasts
Mixed Myelodysplastic/Myeloproliferative Disease

Interventions

DRUG: Azacitidine
OTHER: Donor lymphocytes
OTHER: Tapering of immune suppression

Sponsor

Karolinska University Hospital

Collaborators

[object Object]